GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.

GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...

GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and up 4% on constant currency. The analysts estimated sales of $9.58 billion.

Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains. The post ...

GSK plans to buy back £2 billion (S$3.4 billion) of shares as it raised its long-term growth outlook on optimism around its ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

In 2021, GSK and Oxford established the Institute of Molecular and Computational Medicine to drive forward the research and ...

Markets have hardly recovered from the DeepSeek shock and have just met trade tariff headwinds. Nonetheless, these stocks are ...

A new cancer vaccine is being created to analyse how pre-cancerous cells develop to target the disease before it takes hold.

Prevention Programme, aimed at exploring the potential of cancer prevention through vaccination. The programme will bring together the expertise of GSK and Oxford in the science of the immune ...

GSK has claimed its second breakthrough designation ... stage small-cell lung cancer (SCLC), with the EMA awarding Priority Medicine (PRIME) status to the drug for this use last year.

A new computational tool could help researchers identify promising drug combinations for treating cancer, according to a new ...